Thus, combinatorial treatment strategies involving GSK126, could potentially increase therapeutic efficacy by inhibiting immune evasion and increasing immune cell trafficking to the tumor; providing a potential rational combination with other immunotherapy regimens under investigation for primary brain tumors including checkpoint blockade using anti- PD-1 and/or anti-CTLA-4. The gene discussed is RPL17; the disease is neoplasm.